Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
2.54 ^USD	+2.42%		-3.42%	+19.25%

05-21	Erasca Closes Oversubscribed Share Offering to Raise $184 Million	MT
05-17	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	MT

Erasca, Inc. Presents Initial Phase 1B Dose Escalation Data from Flagshp-1 for Eras-601 Plus Cetuximab in Patients with Advanced Solid Tumors At the 2023 AACR Annual Meeting

April 18, 2023 at 09:00 am

Erasca, Inc. presented promising initial Phase 1b dose escalation data from FLAGSHP-1 for ERAS-601 in combination with cetuximab (ERBITUX®?) in patients with advanced solid tumors as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida. ERAS-601 is a potent, selective, oral small molecule SHP2 inhibitor with best-in-class potential.

Latest news about Erasca, Inc.

Erasca Closes Oversubscribed Share Offering to Raise $184 Million	05-21	MT
Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	05-17	MT
Erasca Prices $160 Million Common Stock Offering	05-17	MT
Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	04-02	MT
Erasca, Inc. announced that it has received $45 million in funding	04-01	CI
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Erasca, Inc. announced that it expects to receive $45 million in funding	03-26	CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target	03-11	MT
Erasca Enters Two Supply Deals With Novartis for Trametinib	02-14	MT
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	02-14	CI
North American Morning Briefing : Boeing Drags -2-	01-08	DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	12-11	CI
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	12-07	MT
HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating	11-28	MT
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	11-28	MT
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	11-28	CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target	23-10-11	MT
Erasca Shares Jump After CEO Stock Purchase Disclosed	23-10-10	MT
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing	23-10-10	MT
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors	23-08-29	MT
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart Erasca, Inc.

Duration

Period

More charts

Company Profile

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Sector

Biotechnology & Medical Research

Calendar

10:00am - American Society of Clinical Oncology Meeting - Abstract Number : TPS3178

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.52 USD

Average target price

5.375 USD

Spread / Average Target

+113.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ERASCA, INC.	+19.25%	692M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research